Nucleic acids: the building blocks of life and the future of medicine?

​Teaser
Nucleic acids are more than carriers of genetic information. They are programmable molecules that can serve as diagnostics, therapeutics, vaccine platforms, and even as building blocks for molecular machines and biological computation.
This session brings together teams across the value chain, from logistics and storage to advanced therapeutic applications, to explore how biological programmability can be translated into robust and scalable medical products.

Why is this topic relevant?
Medicine is shifting toward programmable and personalized approaches. Platforms that can be rapidly designed, modified, and combined have the potential to accelerate development and unlock new classes of therapies. This is where nucleic acids have a clear structural advantage.
They are modular, information-driven, and inherently adaptable, enabling diagnostics, gene regulation, and highly targeted interventions. At the same time, major challenges remain, including stability, delivery to specific cells and tissues, immune responses, manufacturing consistency, cost, and regulatory validation.
What is at stake is not incremental progress, but platform dominance. The decisions being made now will determine whether nucleic acids remain a niche technology or become the foundation of next-generation medicine.

The session will take place on the VITALA Planet at VENTURE SPRIND 2026, held at Futurium in Berlin. You will need a VENTURE SPRIND ticket to enter the venue and attend the session.
If you don’t have one yet but are an active investor, just drop us a line at [email protected] - there’s a good chance we can sort you out with a ticket. Availability is limited.